Swedbank AB Has $136.83 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Swedbank AB increased its stake in Jazz Pharmaceuticals by 10.0% in Q1, owning 1,102,143 shares worth approximately $136.83 million.
• Wall Street analysts have given Jazz Pharmaceuticals a consensus rating of "Moderate Buy." Several firms, including Morgan Stanley and Truist Financial, have recently raised their price targets for the stock.
• Jazz Pharmaceuticals reported a quarterly net loss of ($8.25) EPS, missing estimates, but had revenue of $1.05 billion, reflecting a 2.1% increase compared to the previous year.

Swedbank AB boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 10.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,102,143 shares of the specialty pharmaceutical company's stock after purchasing an additional 100,211 shares during the period. Swedbank AB owned 1.82% of Jazz Pharmaceuticals worth $136,831,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Voya Investment Management LLC increased its holdings in Jazz Pharmaceuticals by 67.1% in the 1st quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company's stock worth $6,996,000 after purchasing an additional 22,628 shares in the last quarter. Inspire Investing LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth about $689,000. Strs Ohio acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth about $2,042,000. Acadian Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the 1st quarter worth about $90,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 137 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JAZZ. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Truist Financial upped their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Royal Bank Of Canada increased their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Finally, Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $178.67.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $128.46 on Friday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The business has a fifty day simple moving average of $118.26 and a two-hundred day simple moving average of $116.82. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a market capitalization of $7.79 billion, a P/E ratio of -19.09, a P/E/G ratio of 7.87 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same period in the prior year, the business earned $5.30 earnings per share. The business's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the sale, the director owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.